Elimination of Latently HIV-1-Infected Cells by Lymphoblasts Armed with Bifunctional Antibody
摘要:
AbstractThe Fab′ fragment of a monoclonal antibody (mAb) to CD3 and the F(ab′)2 fragment of a mAb to human immunodeficiency virus 1 (HIV‐1) gp41 were combined to generate a bifunctional antibody (BFA). The mAb to gp41 (IV1‐4G6) has previously been shown to react with a number of HIV‐1 strains and T‐lymphoblastoid cells (TLBC) armed with the BFA (BFA‐TLBC) effectively inhibited HIV‐1 in primarily cultured lymphoblasts infected with the clinically isolated virus which was reactive to the mAb. Although BFA‐TLBC could not cause cytolysis of 51Cr‐labeled latently infected cells (OM‐10.1) in 6 hr incubation, cocultivation of OM‐10.1 cells with BFA‐TLBC for 3 days or more eliminated the latently infected cells making the cells susceptible to BFA‐TLBC. Therefore, BFA‐TLBC may be beneficial for HIV‐infected patients in eradicating latently infected cells which can not be eliminated even with highly active antiretroviral therapy (HAART).
Synthesis of a key intermediate in the diaminopimelate pathway to L-Lysine: 2,3,4,5-tetrahydrodipicolinic acid
摘要:
2,3,4,5-Tetrahydrodipicolinic acid (3) is a key intermediate in the diaminopimelate (DAP) pathway to L-lysine (7). It was synthesized as the stable racemic potassium salt (25) from dipicolinic acid (14) by esterification, hydrogenation to the cis-diester (17), followed by elimination of p-toluenesuifinic acid from the N-toluenesulfonyl derivative (24) of dimethyl cis-piperidine-2,6-dicarboxylate with concomitant cleavage of the ester groups. (+/-)-2,3,4,5-Tetrahydrodipicolinic acid is unstable in neutral or acidic solution, and in basic solution it exists in equilibrium with the corresponding enamine (27) and 2-oxo-6-aminoadipate (26).
[EN] COMPOUNDS USEFUL AS IMMUNOMODULATORS<br/>[FR] COMPOSÉS UTILES COMME IMMUNOMODULATEURS
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2015034820A1
公开(公告)日:2015-03-12
Disclosed are compounds of Formula (I): (I). Also disclosed are methods of using such compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of virological diseases or disorders and cancer.
Disclosed are compounds of Formula (I): (I). Also disclosed are methods of using such compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of virological diseases or disorders and cancer.